The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CFX | -34.19% | -77.82% | -25.99% | -17% |
| S&P | +13.19% | +87.83% | +13.42% | +382% |
Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.
Investors fear the cost of an expansion into orthopedics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $548.91M | 8.6% |
| Gross Profit | $286.72M | 16.4% |
| Gross Margin | 52.23% | 3.5% |
| Market Cap | $1.73B | -27.9% |
| Market Cap / Employee | $0.24M | 0.0% |
| Employees | 7.4K | 12.5% |
| Net Income | -$570.87M | -1603.8% |
| EBITDA | $83.42M | 21.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $33.62M | -5.1% |
| Accounts Receivable | $431.77M | 7.9% |
| Inventory | 613.8 | 0.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.40B | 1.8% |
| Short Term Debt | $44.03M | 5.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.39% | -25.0% |
| Return On Invested Capital | -4.83% | -4.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $29.09M | 1128.3% |
| Operating Free Cash Flow | $82.58M | 54.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.74 | 0.83 | 0.68 | 0.67 | -6.40% |
| Price to Sales | 1.16 | 0.86 | 0.88 | 0.82 | -32.44% |
| Price to Tangible Book Value | -5.33 | -4.77 | -3.89 | -3.18 | -39.73% |
| Price to Free Cash Flow TTM | 239.60 | 80.41 | - | ||
| Enterprise Value to EBITDA | 43.28 | 80.49 | 48.40 | 38.85 | -29.97% |
| Free Cash Flow Yield | 0.4% | 1.2% | - | ||
| Return on Equity | -27.7% | -27.4% | -28.3% | -51.1% | 1325.22% |
| Total Debt | $1.40B | $1.46B | $1.46B | $1.44B | 1.90% |
No podcast episodes available.
CFX earnings call for the period ending June 30, 2021.
CFX earnings call for the period ending June 30, 2021.
CFX earnings call for the period ending April 3, 2021.
CFX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
